Mats-Olof Wallin, who recently took on the role as interim Chief Financial Officer (CFO), has been appointed Senior Vice President and CFO at Swedish Orphan Biovitrum AB (publ.) (Sobi).
After a thorough search process supported by a senior Executive Search firm,
Mats-Olof Wallin was selected as the preferred candidate. Wallin brings more
than 30 years of experience in the pharmaceutical industry, gained from various
executive positions within companies such as Pharmacia, Ortivus and, most
recently, Biotage AB (publ.) where he held the role of CFO between 2003 and
2011. Wallin has been working at Sobi for the past several months.
"We are very pleased with the appointment of Mats-Olof as our permanent CFO. We
have conducted a thorough search process and Mats-Olof has emerged as the most
suitable candidate for the job. He brings significant experience to the role and
has already proven to be a great addition to our senior team", said CEO Geoffrey
McDonough.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not for
publication
Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
Investor Relations
T: +46 70 410 71 80 T: +46 8 697 20 00
[email protected] [email protected]
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.